Human kinetics of orally and intravenously administered low-dose 1,2- 13C-dichloroacetate

Journal of Clinical Pharmacology

Volumn 46, Issue 12, 2006, Pages 1449-1459

  Jia, Minghong ^a   Coats, Bonnie ^b   Chadha, Monisha ^b   Frentzen, Barbara ^a   Perez Rodriguez, Javier ^b   Chadik, Paul A ^a   Yost, Richard A ^c   Henderson, George N ^a,b   Stacpoole, Peter W ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Dichloroacetate; Disinfection by products; Environmental toxicology; Pharmacokinetics

Indexed keywords

DICHLOROACETIC ACID;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG URINE LEVEL; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; NORMAL HUMAN; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CARBON ISOTOPES; DICHLOROACETATE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENVIRONMENTAL EXPOSURE; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; SOFTWARE; TIME FACTORS;

EID: 33750744414     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006292627     Document Type: Article

References (47)

1. Stacpoole PW, Henderson GN, Yan Z, James MO. Clinical pharmacology and toxicology of dichloroacetate. Environ Health Perspect. 1998;106(suppl 4):989-994.
2. Stacpoole PW. The pharmacology of dichloroacetate. Metabolism. 1989;38:1124-1144.
3. Sanchez IM, Bull RJ. Early induction of reparative hyperplasia in the liver of B6C3F1 mice treated with dichloroacetate and trichloroacetate. Toxicology. 1990;64:33-46.
4. Naito E, Kuroda Y, Toshima K, et al. Effect of sodium dichloroacetate on human pyruvate metabolism. Brain Dev. 1989;11;195-197.
5. DeAngelo AB, Daniel FB, Stober JA, Olson GR. The carcinogenicity of dichloroacetic acid in the male B6C3F1 mouse. Fundam Appl Toxicol. 1991;16:337-347.
6. DeAngelo AB, Daniel FB, Most BM, Olson GR. The carcinogenicity of dichloroacetic acid in the male Fischer 344 rat. Toxicology. 1996;114:207-221.
7. Bull RJ, Sanchez IM, Nelson MA, Larson JL, Lansing AJ. Liver tumor induction in B6C3F1 mice by dichloroacetate and trichloroacetate. Toxicology. 1990;63:341-359.
8. Spruijt L, Naviaux RK, McGowan KA, et al. Nerve conduction changes in patients with mitochondrial diseases treated with dichloroacetate. Muscle Nerve. 2001;24:916-924.
9. Kurlemann G, Paetzke I, Moller H, et al. Therapy of complex I deficiency: peripheral neuropathy during dichloroacetate therapy. Eur J Pediatr. 1995;154:928-932.
10. Yang HM, Davis ME. Dichloroacetic acid pretreatment of male and female rats increases chloroform-induced hepatotoxicity. Toxicology. 1997;124:63-72.
11. McHugh LJ, Lopez L, DeAngelo AB. Hepatotoxicity of the drinking water disinfection by-product, dichloroacetic acid, in the medaka small fish model. Toxicol Lett. 1998;94:19-27.
12. Moser VC, Phillips PM, McDaniel KL, MacPhail RC. Behavioral evaluation of the neurotoxicity produced by dichloroacetic acid in rats. Neurotoxicol Teratol. 1999;21:719-731.
13. Jolley RL. Basic issues in water chlorination: a chemical perspective. In: Water Chlorination: Chemistry, Environmental Impact and Health Effects. Vol. 5. Chelsea, Mich: Lewis; 1985:19-38.
14. Uden PC, Miller JW. Chlorinated acids and chloral in drinking water. J Am Water Works Assoc. 1983;75:524-527.
15. Rompp A, Klemm O, Fricke W, Frank H. Haloacetates in fog and rain. Environ Sci Technol. 2001;35:1294-1298.
16. Lim CE, Matthaei KI, Blackburn AC, et al. Mice deficient in glutathione transferase zeta/maleylacetoacetate isomerase exhibit a range of pathological changes and elevated expression of alpha, mu, and pi class glutathione transferases. Am J Pathol. 2004;165:679-693.
17. Dixon DP, Cole DJ, Edwards R. Characterization of a zeta class glutathione transferase from Arabidopsis thaliana with a putative role in tyrosine catabolism. Arch Biochem Biophys. 2000;384:407-412.
18. Schultz IR, Merdink JL, Gonzalez-Leon A, Bull RJ. Dichloroacetate toxicokinetics and disruption of tyrosine catabolism in B6C3F1 mice: dose-response relationships and age as a modifying factor. Toxicology. 2002;173:229-247.
19. Cornett R, James MO, Henderson GN, Cheung J, Shroads AL, Stacpoole PW. Inhibition of glutathione S-transferase zeta and tyrosine metabolism by dichloroacetate: a potential unifying mechanism for its altered biotransformation and toxicity. Biochem Biophys Res Commun. 1999;262:752-756.
20. Ammini CV, Stacpoole PW: Biotransformation, toxicology and pharmacogenomics of dichloroacetate. In: Natural Production of Organohalogen Compounds. Gribble GW, ed. Vol. 3/P. The Handbook of Environmental Chemistry series. New York, NY: Springer-Verlag; 2003:215-234.
21. Jia M, Wu WW, Yost RA, Chadik PA, Stacpoole PW, Henderson GN. Simultaneous determination of trace levels of nine haloacetic acids in biological samples as their pentafluorobenzyl derivatives by gas chromatography/tandem mass spectrometry in electron capture negative ion chemical ionization mode. Anal Chem. 2003;75:4065-4080.
22. Chu PI, Curry SH, Baumgartner TG, Henderson GN, Stacpoole PW. Preparation and stability of intravenous solutions of sodium dichloroacetate (DCA). J Parenter Sci Technol. 1992;46:16-18.
23. Stacpoole PW, Henderson GN, Yan Z, Cornett R, James MO. Pharmacokinetics, metabolism and toxicology of dichloroacetate. Drug Metab Rev. 1998;30:499-539.
24. James MO, Cornett R, Yan Z, Henderson GN, Stacpoole PW. Glutathione-dependent conversion to glyoxylate, a major pathway of dichloroacetate biotransformation in hepatic cytosol from humans and rats, is reduced in dichloroacetate-treated rats. Drug Metab Dispos. 1997;25:1223-1227.
25. Ammini CV, Fernandez-Canon J, Shroads AL, et al. Pharmacologic or genetic ablation of maleylacetoacetate isomerase increases levels of toxic tyrosine catabolites in rodents. Biochem Pharmacol. 2003;66:2029-2038.
26. Anderson WB, Liebler DC, Board PG, Anders MW. Mass spectral characterization of dichloroacetic acid-modified human glutathione transferase zeta. Chem Res Toxicol. 2002;15:1387-1397.
27. Dixit V, James MO, Henderson GN, Stacpoole PW. Modification of the glutathione-binding site of human GSTz1-1 by the dichloroacetate metabolite, glyoxylate. Presented at: 13th North American ISSC Meeting/20th JSSX Meeting; October 23-27, 2005; Maui, HI.
28. Guo X, Dixit VS, Liu HP, et al. Inhibition and recovery of rat hepatic glutathione S-transferase zeta and alteration of tyrosine metabolism following dichloroacetate exposure and withdrawal. Drug Metab Dispos. 2006;34:36-42.
29. Shroads AL, Henderson GN, Cheung J, James MO, Stacpoole PW. Unified gas chromatographic-mass spectrometric method for quantitating tyrosine metabolites in urine and plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;808:153-161.
30. Lim CE, Matthaei KI, Blackburn AC, et al. Mice deficient in glutathione transferase zeta/maleylacetoacetate isomerase exhibit a range of pathological changes and elevated expression of alpha, mu, and pi class glutathione transferases. Am J Pathol. 2004;165: 679-693.
31. Kaufmann P, Engelstad K, Wei Y, et al. Dichloroacetate as a treatment for MELAS: a randomized, controlled clinical trial. Neurology. 2006;66:324-330.
32. Stacpoole PW, Kerr DS, Barnes C, et al. A controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics. 2006;117:1519-1521.
33. Stacpoole PW, Shroads AL, Felitsyn NM, Notterpek L, Calcutt NA. Mechanism of age dependence of dichloroacetate-induced peripheral neuropathy. Presented at: United Mitochondrial Disease Foundation; June 14-18, 2006; Atlanta, Ga.
34. Tzeng H, Blackburn AC, Board PG, Anders MW. Polymorphism and species-dependent inactivation of glutathione transferase zeta by dichloroacetate. Chem Res Toxicol. 2000;13:231-236.
35. Schultz IR, Shangraw RE. Effect of short-term drinking water exposure to dichloroacetate on its pharmacokinetics and oral bioavailability in human volunteers: a stable isotope study. Toxicol Sci. 2006;92:42-50.
36. 14C] dichloroacetate in male Sprague-Dawley rats. Identification of glycine conjugates, including hippurate, as urinary metabolites of dichloroacetate. Drug Metab Dispos. 1998;26:1134-1143.
37. Curry SH, Lorenz A, Chu PI, Limacher M, Stacpoole PW. Disposition and pharmacodynamics of dichloroacetate (DCA) and oxalate following oral DCA doses. Biopharm Drug Dispos. 1991;12:375-390.
38. Saghir SA, Schultz IR. Low-dose pharmacokinetics and oral bioavailability of dichloroacetate in naive and GST-zeta-depleted rats. Environ Health Perspect. 2002;110:757-763.
39. Saghir SA, Schultz IR. Toxicokinetics and oral bioavailability of halogenated acetic acids mixtures in naive and GSTzeta-depleted rats. Toxicol Sci. 2005;84:214-224.
40. Wells PG, Moore GW, Rabin D, Wilkinson GR, Oates JA, Stacpoole PW. Metabolic effects and pharmacokinetics of intravenously administered dichloroacetate in humans. Diabetologia. 1980;19:109-113.
41. Agbenyega T, Angus BJ, Bedu-Addo G, et al. Glucose and lactate kinetics in children with severe malaria. J Clin Endocrinol Metab. 2000;85:1569-1576.
42. 13C-DCA in humans. Presented at: American Society of Mass Spectrometry; June 5-9, 2005; San Antonio, Tex.
43. Krishna S, Agbenyega T, Angus BJ, et al. Pharmacokinetics and pharmacodynamics of dichloroacetate in children with lactic acidosis due to severe malaria. QJM. 1995;88:341-349.
44. Agbenyega T, Planche T, Bedu-Addo G, et al. Population kinetics, efficacy, and safety of dichloroacetate for lactic acidosis due to severe malaria in children. J Clin Pharmacol. 2003;43:386-396.
45. Stacpoole PW, Wright EC, Baumgartner TG, et al. A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. The Dichloroacetate-Lactic Acidosis Study Group. N Engl J Med. 1992;27:1564-1569.
46. Curry SH, Chu PI, Baumgartner TG, Stacpoole PW. Plasma concentrations and metabolic effects of intravenous sodium dichloroacetate. Clin Pharmacol Ther. 1985;37:89-93.
47. Henderson GN, Curry SH, Derendorf H, Wright EC, Stacpoole PW. Pharmacokinetics of dichloroacetate in adult patients with lactic acidosis. J Clin Pharmacol. 1997;37:416-425.